Andrew Phillips

Andrew Phillips focuses on the clinical implications of tumor dormancy for adjuvant therapy decisions, investigating how knowledge of dormancy biology should inform the duration and type of adjuvant treatment to prevent late metastatic recurrence in breast cancer and other solid tumors. His clinical research has evaluated extended adjuvant endocrine therapy beyond five years and the role of ctDNA monitoring in detecting dormant disease reactivation. He has developed risk models incorporating dormancy biomarkers to personalize adjuvant therapy duration. His translational research bridges dormancy biology with evidence-based clinical oncology to improve long-term cancer outcomes.